These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

536 related items for PubMed ID: 32781914

  • 1. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.
    Koehler VF, Adam P, Frank-Raue K, Raue F, Berg E, Hoster E, Allelein S, Schott M, Kroiss M, Spitzweg C.
    Thyroid; 2021 Mar; 31(3):459-469. PubMed ID: 32781914
    [Abstract] [Full Text] [Related]

  • 2. Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
    Tappenden P, Carroll C, Hamilton J, Kaltenthaler E, Wong R, Wadsley J, Moss L, Balasubramanian S.
    Health Technol Assess; 2019 Feb; 23(8):1-144. PubMed ID: 30821231
    [Abstract] [Full Text] [Related]

  • 3. Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort.
    Chougnet CN, Borget I, Leboulleux S, de la Fouchardiere C, Bonichon F, Criniere L, Niccoli P, Bardet S, Schneegans O, Zanetta S, Schvartz C, Drui D, Chauffert B, Rohmer V, Schlumberger M.
    Thyroid; 2015 Apr; 25(4):386-91. PubMed ID: 25627619
    [Abstract] [Full Text] [Related]

  • 4. Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience.
    Kim M, Yoon JH, Ahn J, Jeon MJ, Kim HK, Lim DJ, Kang HC, Kim IJ, Shong YK, Kim TY, Kim BH.
    Endocrinol Metab (Seoul); 2020 Sep; 35(3):587-594. PubMed ID: 32981301
    [Abstract] [Full Text] [Related]

  • 5. cabozantinib (COMETRIQ⁰). In medullary thyroid cancer: more harmful than beneficial, as is vandetanib.
    Prescrire Int; 2016 Jan; 25(167):11-3. PubMed ID: 26942253
    [Abstract] [Full Text] [Related]

  • 6. Continued Discontinuation of TKI Treatment in Medullary Thyroid Carcinoma - Lessons From Individual Cases With Long-Term Follow-Up.
    Brandenburg T, Tiedje V, Muchalla P, Theurer S, Weber F, Schmid KW, Dralle H, Führer D.
    Front Endocrinol (Lausanne); 2021 Jan; 12():718418. PubMed ID: 34659114
    [Abstract] [Full Text] [Related]

  • 7. Medullary thyroid carcinoma - Adverse events during systemic treatment: risk-benefit ratio.
    Maciel LMZ, Magalhães PKR.
    Arch Endocrinol Metab; 2017 Jan; 61(4):398-402. PubMed ID: 28658345
    [Abstract] [Full Text] [Related]

  • 8. Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension.
    Milling RV, Grimm D, Krüger M, Grosse J, Kopp S, Bauer J, Infanger M, Wehland M.
    Int J Mol Sci; 2018 Oct 20; 19(10):. PubMed ID: 30347815
    [Abstract] [Full Text] [Related]

  • 9. Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001.
    Wirth LJ, Brose MS, Subbiah V, Worden F, Solomon B, Robinson B, Hadoux J, Tomasini P, Weiler D, Deschler-Baier B, Tan DSW, Maeda P, Lin Y, Singh R, Bayt T, Drilon A, Cassier PA.
    J Clin Oncol; 2024 Sep 20; 42(27):3187-3195. PubMed ID: 39094065
    [Abstract] [Full Text] [Related]

  • 10. Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer.
    Krajewska J, Olczyk T, Jarzab B.
    Expert Rev Clin Pharmacol; 2016 Sep 20; 9(1):69-79. PubMed ID: 26536165
    [Abstract] [Full Text] [Related]

  • 11. Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
    de Castroneves LA, Negrão MV, de Freitas RM, Papadia C, Lima JV, Fukushima JT, Simão EF, Kulcsar MA, Tavares MR, Jorge AA, de Castro G, Hoff PM, Hoff AO.
    Thyroid; 2016 Mar 20; 26(3):414-9. PubMed ID: 26701095
    [Abstract] [Full Text] [Related]

  • 12. Cabozantinib in progressive medullary thyroid cancer.
    Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI.
    J Clin Oncol; 2013 Oct 10; 31(29):3639-46. PubMed ID: 24002501
    [Abstract] [Full Text] [Related]

  • 13. The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer.
    Fallahi P, Ferrari SM, Baldini E, Biricotti M, Ulisse S, Materazzi G, Miccoli P, Antonelli A.
    Expert Rev Anticancer Ther; 2016 Nov 10; 16(11):1109-1118. PubMed ID: 27650489
    [Abstract] [Full Text] [Related]

  • 14. Systemic treatment and management approaches for medullary thyroid cancer.
    Ernani V, Kumar M, Chen AY, Owonikoko TK.
    Cancer Treat Rev; 2016 Nov 10; 50():89-98. PubMed ID: 27664392
    [Abstract] [Full Text] [Related]

  • 15. SAFETY AND TOLERABILITY OF VANDETANIB IN JAPANESE PATIENTS WITH MEDULLARY THYROID CANCER: A PHASE I/II OPEN-LABEL STUDY.
    Uchino K, Komoda M, Tomomatsu J, Okamoto T, Horiuchi K, Tsuji A, Ito Y, Todo T, Rito K, Takahashi S.
    Endocr Pract; 2017 Feb 10; 23(2):149-156. PubMed ID: 27819766
    [Abstract] [Full Text] [Related]

  • 16. Predictive Value of 18F-FDG PET in Patients with Advanced Medullary Thyroid Carcinoma Treated with Vandetanib.
    Werner RA, Schmid JS, Higuchi T, Javadi MS, Rowe SP, Märkl B, Aulmann C, Fassnacht M, Kroiss M, Reiners C, Buck AK, Kreissl MC, Lapa C.
    J Nucl Med; 2018 May 10; 59(5):756-761. PubMed ID: 29025983
    [Abstract] [Full Text] [Related]

  • 17. Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model.
    Carra S, Gaudenzi G, Dicitore A, Saronni D, Cantone MC, Plebani A, Ghilardi A, Borghi MO, Hofland LJ, Persani L, Vitale G.
    Int J Mol Sci; 2021 Mar 16; 22(6):. PubMed ID: 33809722
    [Abstract] [Full Text] [Related]

  • 18. The safety of vandetanib for the treatment of thyroid cancer.
    Tsang VH, Robinson BG, Learoyd DL.
    Expert Opin Drug Saf; 2016 Aug 16; 15(8):1107-13. PubMed ID: 27301016
    [Abstract] [Full Text] [Related]

  • 19. Vandetanib for the treatment of medullary thyroid cancer.
    Chau NG, Haddad RI.
    Clin Cancer Res; 2013 Feb 01; 19(3):524-9. PubMed ID: 23231950
    [Abstract] [Full Text] [Related]

  • 20. Novel therapies for thyroid cancer.
    Krajewska J, Jarzab B.
    Expert Opin Pharmacother; 2014 Dec 01; 15(18):2641-52. PubMed ID: 25318585
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.